Company profile IDYA

Ideaya Biosciences Inc
ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene..., wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california. Show More
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences -synthetic lethality-focused precision medicine oncology company to provide analysis

Correlation between past revenue and IDEAYA Biosciences -synthetic lethality-focused precision medicine oncology company search interest

There is not enough data for IDEAYA Biosciences -synthetic lethality-focused precision medicine oncology company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences -synthetic lethality-focused precision medicine oncology company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences news to provide analysis

Correlation between past revenue and IDEAYA Biosciences news search interest

There is not enough data for IDEAYA Biosciences news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 15:09:30.

After 39 days of this quarter the interest is at 108.0. Based on that we can calculate that during remaining 52 days it will total up to 252.0.
IDEAYA Biosciences stock expected interest is significantly higher compared to previous quarter (+59.5%) and same quarter last year (+260.0%).

YearQ1Q2Q3Q4
20190
107
inf% QoQ
118
10.3% QoQ
132
11.9% QoQ
2020 196
inf% YoY 48.5% QoQ
132
23.4% YoY -32.7% QoQ
96
-18.6% YoY -27.3% QoQ
61
-53.8% YoY -36.5% QoQ
2021 63
-67.9% YoY 3.3% QoQ
109
-17.4% YoY 73.0% QoQ
54
-43.8% YoY -50.5% QoQ
0
-100.0% YoY -100.0% QoQ
2022 165
161.9% YoY inf% QoQ
60
-45.0% YoY -63.6% QoQ
54
0.0% YoY -10.0% QoQ
92
inf% YoY 70.4% QoQ
2023 70
-57.6% YoY -23.9% QoQ
185
208.3% YoY 164.3% QoQ
35
-35.2% YoY -81.1% QoQ
158
71.7% YoY 351.4% QoQ
2024 108
54.3% YoY -31.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and IDEAYA Biosciences stock search interestLast update: February 09 2024 15:09:29.
Correlation coefficient between keyword and revenue is -0.11
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 15:09:31.

The average 5 years interest of IDEAYA Biosciences stock was 7.64 per week.
The last year interest of IDEAYA Biosciences stock compared to the last 5 years has changed by 22.38%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 1.3%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences clinical trials to provide analysis

Correlation between past revenue and IDEAYA Biosciences clinical trials search interest

There is not enough data for IDEAYA Biosciences clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences pipeline to provide analysis

Correlation between past revenue and IDEAYA Biosciences pipeline search interest

There is not enough data for IDEAYA Biosciences pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences investor relations to provide analysis

Correlation between past revenue and IDEAYA Biosciences investor relations search interest

There is not enough data for IDEAYA Biosciences investor relations to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences investor relations to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences target therapeutics to provide analysis

Correlation between past revenue and IDEAYA Biosciences target therapeutics search interest

There is not enough data for IDEAYA Biosciences target therapeutics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences target therapeutics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences molecular diagnostics to provide analysis

Correlation between past revenue and IDEAYA Biosciences molecular diagnostics search interest

There is not enough data for IDEAYA Biosciences molecular diagnostics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences molecular diagnostics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences precision medicine to provide analysis

Correlation between past revenue and IDEAYA Biosciences precision medicine search interest

There is not enough data for IDEAYA Biosciences precision medicine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences precision medicine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences synthetic lethality to provide analysis

Correlation between past revenue and IDEAYA Biosciences synthetic lethality search interest

There is not enough data for IDEAYA Biosciences synthetic lethality to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences synthetic lethality to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for IDYA
Earnings date: 2024-03-05 After close
Company name: Ideaya Biosciences Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-19T06:00:00-04:00

PR Newswire
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

2026-10-16T14:42:21.923317677Z

Analyst Upgrades
William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating

2026-09-28T06:00:00-04:00

PR Newswire
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

2026-09-25T06:00:00-04:00

PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-09-14T07:00:00-04:00

Earnings Call Transcripts
Morgan Stanley 24th Annual Global Healthcare Conference - IDEAYA BIOSCIENCES INC

2026-09-09T13:12:04.196221069Z

Analyst Upgrades
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57

2026-09-09T06:00:00-04:00

PR Newswire
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

2026-09-01T13:32:13.078059448Z

Analyst Upgrades
Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target

2026-09-01T06:00:00-04:00

PR Newswire
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences

2026-08-31T06:00:00-04:00

PR Newswire
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

2026-08-28T06:00:00-04:00

PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-08-19T06:00:00-04:00

PR Newswire
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

2026-08-05T18:18:38.306665827Z

Analyst Upgrades
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

2026-08-05T13:20:49.56364928Z

Analyst Upgrades
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

2026-08-04T06:00:00-04:00

PR Newswire
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update